Mereo BioPharma Group PLC ADR

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$1.86-$5.02
Market Cap
$616.9M
Shares Short
5M

Financials

See more
Revenue (12 Mos)
$1M
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$936,000
Diluted EPS
-$0.25

News

See more

Yahoo Finance • last year

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Yahoo Finance • last year

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Yahoo Finance • last year

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

Yahoo Finance • last year

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

About

CEO
Dr. Denise Vera Scots-Knight Ph.D.
Address
One Cavendish Place, London, United Kingdom, W1G 0QF
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
33